↓ Skip to main content

Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents

Overview of attention for article published in Annals of Hematology, July 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
52 Mendeley
Title
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents
Published in
Annals of Hematology, July 2015
DOI 10.1007/s00277-015-2462-4
Pubmed ID
Authors

A. Romano, N. L. Parrinello, M. L. Consoli, L. Marchionni, S. Forte, C. Conticello, A. Pompa, A. Corso, G. Milone, F. Di Raimondo, I. Borrello

Abstract

Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4-15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR < 2. Among younger patients (age <65 years, N = 179), NLR ≥ 2 had a negative prognostic impact on both PFS and OS, in all ISS stages. By combining ISS stage and NLR in a model limited to young patients, we found that 19 % of the patients were classified as very low risk, 70 % standard risk and 11 % very high risk. The 5-year estimates were 39.3, 19.4 and 10.9 % for PFS and 95.8, 50.9 and 23.6 % for OS for very low, standard-risk and very high-risk groups. We found NLR to be a predictor of PFS and OS in MM patients treated upfront with novel agents. NLR can be combined with ISS staging system to identify patients with dismal outcome. However, larger cohorts and prospective studies are needed to use NLR as additional parameter to personalise MM therapy in the era of novel agents.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 17%
Student > Ph. D. Student 7 13%
Student > Bachelor 6 12%
Other 6 12%
Student > Postgraduate 4 8%
Other 10 19%
Unknown 10 19%
Readers by discipline Count As %
Medicine and Dentistry 28 54%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Nursing and Health Professions 3 6%
Biochemistry, Genetics and Molecular Biology 1 2%
Agricultural and Biological Sciences 1 2%
Other 3 6%
Unknown 13 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2015.
All research outputs
#17,773,420
of 22,828,180 outputs
Outputs from Annals of Hematology
#1,357
of 2,167 outputs
Outputs of similar age
#176,501
of 262,905 outputs
Outputs of similar age from Annals of Hematology
#7
of 21 outputs
Altmetric has tracked 22,828,180 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,167 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,905 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.